ARAF is altered in 1.6% of malignant solid tumor patients with ARAF Mutation present in 1.21% of all malignant solid tumor patients [4].

ARAF Mutation is an inclusion criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain ARAF Mutation and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open) [5].

ARAF is altered in 1.87% of non-small cell lung carcinoma patients with ARAF Mutation present in 1.46% of all non-small cell lung carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ARAF Mutation and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

ARAF is altered in 2.42% of melanoma patients with ARAF Mutation present in 2.22% of all melanoma patients [4].

ARAF Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain ARAF Mutation and melanoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [5].

ARAF is altered in 0.79% of non-hodgkin lymphoma patients with ARAF Mutation present in 0.33% of all non-hodgkin lymphoma patients [4].

ARAF Mutation is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARAF Mutation and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

ARAF is altered in 2.2% of colorectal carcinoma patients with ARAF Mutation present in 1.97% of all colorectal carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.57% of histiocytic and dendritic cell neoplasm patients with ARAF Mutation present in 1.57% of all histiocytic and dendritic cell neoplasm patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ARAF Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

ARAF is altered in 1.08% of glioma patients with ARAF Mutation present in 0.98% of all glioma patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF Mutation and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ARAF is altered in 0.9% of low grade glioma patients with ARAF Mutation present in 0.79% of all low grade glioma patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 2.48% of ovarian carcinoma patients with ARAF Mutation present in 0.65% of all ovarian carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.51% of thyroid gland carcinoma patients with ARAF Mutation present in 0.51% of all thyroid gland carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ARAF is altered in 5.05% of endometrial carcinoma patients with ARAF Mutation present in 4.35% of all endometrial carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 3.03% of pancreatic ductal adenocarcinoma patients with ARAF Mutation present in 3.03% of all pancreatic ductal adenocarcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARAF is altered in 2.52% of cutaneous melanoma patients with ARAF Mutation present in 2.43% of all cutaneous melanoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARAF is altered in 1.49% of schwannoma patients with ARAF Mutation present in 1.49% of all schwannoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.89% of squamous cell lung carcinoma patients with ARAF Mutation present in 1.29% of all squamous cell lung carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.19% of ganglioglioma patients with ARAF Mutation present in 1.19% of all ganglioglioma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 3.49% of malignant peripheral nerve sheath tumor patients with ARAF Mutation present in 1.16% of all malignant peripheral nerve sheath tumor patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.29% of diffuse glioma patients with ARAF Mutation present in 1.15% of all diffuse glioma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.42% of hepatocellular carcinoma patients with ARAF Mutation present in 1.13% of all hepatocellular carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF is altered in 1.13% of astrocytic tumor patients with ARAF Mutation present in 1.01% of all astrocytic tumor patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 1.09% of breast carcinoma patients with ARAF Mutation present in 0.76% of all breast carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.61% of neuronal and mixed neuronal-glial tumors patients with ARAF Mutation present in 0.61% of all neuronal and mixed neuronal-glial tumors patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.87% of soft tissue sarcoma patients with ARAF Mutation present in 0.56% of all soft tissue sarcoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.44% of renal cell carcinoma patients with ARAF Mutation present in 0.44% of all renal cell carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.4% of pancreatic carcinoma patients with ARAF Mutation present in 0.36% of all pancreatic carcinoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF is altered in 0.17% of acute myeloid leukemia patients with ARAF Mutation present in 0.17% of all acute myeloid leukemia patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF is altered in 0.82% of neuroblastoma patients [4].

ARAF Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARAF Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].